PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

New insight into antibody-induced protective immunity to COVID-19

Researchers at the Ragon Institute of MGH, MIT and Harvard and the Brigham and Women's Hospital collaborate with SpaceX to identify humoral immune features which may track with lasting protection against SARS-CoV-2.

2021-02-16
(Press-News.org) BOSTON -- While PCR testing has been used widely for COVID-19 diagnosis, it only provides information on who is currently infected. Antibody testing can tell who has been previously exposed to SARS-CoV-2, the virus that causes COVID-19, a metric that is essential for tracking spread across a population. It may also, as a study recently published in the journal Nature Communications shows, hold the key to understanding the immune response to the virus.

Led by Galit Alter, PhD, Core Member of the Ragon Institute of MGH, MIT and Harvard, this study found that while antibodies against SARS-CoV-2 may be a good way to measure exposure to the virus, their presence alone wasn't enough to determine if a person had long-lasting protection. Instead, antibody effector functions associated with long-lasting protection, like virus neutralization and T cell responses, were only seen if the immune response included high levels of antibodies against a part of the virus called the receptor binding domain.

"Essentially," says Alter, who is also a professor of Medicine at Harvard Medical School (HMS), "this study indicates that it's not simply the presence or absence of antibodies that matter; rather, the amount and type of antibodies may play a defining role in the development of a protective immune response."

This data came from a cohort of adults who had mild or asymptomatic cases of COVID-19 (unusual among the studies that started in the early days of the pandemic), the result of a collaboration with SpaceX, an aerospace manufacturer and space transportation services company that was seeking data-driven ways to protect its essential workforce.

The project began in April of 2020 and, along with Alter and her group, included Anil Menon, MD, Medical Director at SpaceX; Doug Lauffenberg, Ford Professor of Biological Engineering, Chemical Engineering, and Biology at MIT; Elon Musk, CEO of SpaceX; and Eric Nilles, MD, Director of the Program on Infectious Diseases and Epidemics at the Harvard Humanitarian Initiative.

"This collaboration with SpaceX that has pulled together immunologists, epidemiologists, molecular and computational biologists and infectious disease modelers is a fantastic example of teamwork across institutions and disciplines, and I'm delighted to see this first publication from these efforts," says Nilles, who is also a professor at HMS and an attending physician at the Brigham and Women's Hospital.

Though the original goal of the study was to measure antibody levels over time, when reports of reinfection began surfacing, Alter's team realized their samples may hold much more valuable information than they originally thought.

"In early spring, we weren't sure if asymptomatic infection could drive long-lived antibodies," says Alter, "nor whether they possessed the capability to neutralize or kill the virus."

The team did know, however, that 120 of their study participants had experienced mild or asymptomatic COVID-19 which had resulted in the development of COVID-19 antibodies. By using sophisticated techniques to delve into these antibody responses, they discovered that individuals who had developed a larger number of antibodies, associated with stronger symptoms in case of mild COVID-19, had also developed immune functions associated with natural immune protection.

"Once you hit a certain threshold of these antibodies, it's like a switch turns on and we can observe antibody effector functions," says Yannic Bartsch, PhD, a Ragon postdoctoral fellow and first author on the study. "These functions were not observed in individuals with lower antibody binding titers, and the level of protection from reinfections is uncertain in these individuals."

Though more work remains to be done, this is an important first step in understanding natural immunity to SARS-CoV-2. With limited availability of COVID-19 vaccines, understanding asymptomatic infection, natural immunity, and who, exactly, is at risk for reinfection, is vital to an effective, successful global vaccine rollout.

INFORMATION:

This work was funded by donations from Nancy Zimmerman, Mark and Lisa Schwartz, an anonymous donor (financial support), and Terry and Susan Ragon, as well as the SAMANA Kay MGH Research Scholars award, and funding from the Ragon Institute of MGH, MIT and Harvard, the Massachusetts Consortium on Pathogen Readiness (MassCPR), the NIH (3R37AI080289-11S1, R01AI146785, U19AI42790-01, U19AI135995-02, U19AI42790-01, 1U01CA260476 - 01, CIVIC75N93019C00052), the Gates Foundation Global Health Vaccine Accelerator Platform funding (OPP1146996 and INV-001650), the Musk Foundation, and the Translational Research Institute for Space Health through NASA Cooperative Agreement NNX16AO69A.

About the Ragon Institute The Ragon Institute of MGH, MIT and Harvard was established in 2009 with a gift from the Phillip T. and Susan M. Ragon Foundation, with a collaborative scientific mission among these institutions to harness the immune system to combat and cure human diseases. Focusing on global infectious diseases, the Ragon Institute draws scientists, clinicians and engineers from diverse backgrounds and areas of expertise to study and understand the immune system with the goal of benefiting patients. For more information, visit http://www.ragoninstitute.org

About the Massachusetts General Hospital Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2020, Mass General was named #6 in the U.S. News & World Report list of "America's Best Hospitals."



ELSE PRESS RELEASES FROM THIS DATE:

Radiomics shows cocaine fuels coronary artery disease risk

2021-02-16
OAK BROOK, Ill. - Radiomics--the extraction of very detailed quantitative features from medical images--provides a refined understanding of how cocaine use and other risk factors affect the course of coronary artery disease, according to a study published in Radiology. Researchers said the study shows the power of radiomics to improve understanding of not just cardiovascular disease, but cancer and other conditions as well. Coronary artery disease typically develops over time as plaque builds up inside the arteries. This process, known as atherosclerosis, ...

COVID-19 linked to potentially dangerous eye abnormalities

COVID-19 linked to potentially dangerous eye abnormalities
2021-02-16
OAK BROOK, Ill. - Researchers using MRI have found significant abnormalities in the eyes of some people with severe COVID-19, according to a study published in the journal Radiology. The study results support the need for eye screening in these patients to provide appropriate treatment and management of potentially severe ophthalmological manifestations of COVID-19. The COVID-19 pandemic has affected more than 100 million people since it began early in 2020. While the virus primarily attacks the lungs, it has been linked with eye abnormalities ...

Global poliovirus risk management and modeling

2021-02-16
Launched in 1988, the Global Polio Eradication Initiative (GPEI) stands out as one of the largest, internationally coordinated global public health major projects conducted to date, with cumulative spending of over $16.5 billion for 1988-2018, according to the World Health Organization (WHO). More than 30 years later, stubborn outbreaks of wild poliovirus still occur in Afghanistan and Pakistan, where cases have been increasing since 2018. The global eradication of polio continues to be an elusive goal. A special issue of the journal Risk Analysis, titled "Global Poliovirus Risk Management and Modeling," looks at the current status of polio eradication ...

Ferns in the mountains

Ferns in the mountains
2021-02-16
Earth is home to millions of known species of plants and animals, but by no means are they distributed evenly. For instance, rainforests cover less than 2 percent of Earth's total surface, yet they are home to 50 percent of Earth's species. Oceans account for 71 percent of Earth's total surface but contain only 15 percent of Earth's species. What drives this uneven distribution of species on Earth is a major question for scientists. In a paper published February 16 in the Journal of Biogeography an international team of researchers led by Jacob S. Suissa, Ph.D. Candidate in the Department of Organismic and Evolutionary Biology, ...

MSK physician shares kidney cancer research at annual ASCO GU Symposium

2021-02-16
Memorial Sloan Kettering Cancer Center (MSK) physicians and scientists presented new research at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium held virtually February 11-13. Notably, MSK medical oncologist Robert Motzer, MD, presented encouraging data from a phase III randomized study that assessed two new treatment combinations as first-line treatments that may prolong survival in people with advanced kidney cancer. Dr. Motzer's findings were also published on February 13 in the New England Journal of Medicine. In this large, international trial involving 200 sites across 20 countries, Dr. Motzer and a team of investigators ...

New classification of leukemia subtypes reveals potential of existing drugs

New classification of leukemia subtypes reveals potential of existing drugs
2021-02-16
Using advanced RNA sequencing, scientists have identified two unique subtypes of a prominent mutation present in many patients with Acute Myeloid Leukemia (AML) - called NPM1 - that could help predict survival and improve treatment response for patients whose leukemic cells bear the mutation. In research published Feb. 16, in Nature Communications, a team led by Princess Margaret Cancer Centre Senior Scientists, Drs. Benjamin Haibe-Kains, Aaron Schimmer and Mark Minden, have discovered that within the NPM1 mutation of AML there exists two unique subtypes, one of which can be effectively treated with drugs already in use. It is the first study to classify within the common NPM1 mutant form of AML two subtypes, one being "primitive" and the other ...

How the immune system paves the way for SARS-CoV-2

How the immune system paves the way for SARS-CoV-2
2021-02-16
Most people infected with SARS-CoV-2 are able to recover from the disease at home - even if they might experience very stressful disease progressions. Some have no symptoms at all. But about ten percent of those affected become so severely ill that they have to be treated in a hospital. The assumption that a weak immune system is behind a severe progression is short-sighted. Especially with critical progressions, the immune system works under intense pressure, but does not manage to control the virus. A Berlin research group has now observed how SARS-CoV-2 uses an immune system defense mechanism to increasingly hijack ...

Story tips: Modeling COVID, permafrost lost and taking the heat

Story tips: Modeling COVID, permafrost lost and taking the heat
2021-02-16
Computing - Modeling COVID dynamics To better understand the spread of SARS-CoV-2, the virus that causes COVID-19, Oak Ridge National Laboratory researchers have harnessed the power of supercomputers to accurately model the spike protein that binds the novel coronavirus to a human cell receptor. These simulations also shed light on the ligand molecules that can inhibit such binding, pointing the way to potential drug therapies. An ultrafast quantum chemical modeling method provides information about the critical electronic interactions between protein and ligand chemicals, going beyond the classical interaction models that are normally employed in computational drug discovery. The findings will enable accurate predictions of the performance of currently available inhibitors ...

Ageing offshore wind turbines could stunt the growth of renewable energy sector

2021-02-16
The University of Kent has led a study highlighting the urgent need for the UK's Government and renewable energy industries to give vital attention to decommissioning offshore wind turbines approaching their end of live expectancy by 2025. The research reveals that the UK must decommission approximately 300 and 1600 early-model offshore wind turbines by 2025 and 2030, respectively. Urgent focus is needed now to proactively use the remaining years until turbines installed in the 1990s and early 2000s are no longer safely functional in 2025, to prevent safety lapses, potentially huge costs and the irretrievable loss of the skillset required for safe decommission. The research shows that these original turbines have an approximate lifetime of 20 to 25 years, but this expectation ...

Breakthrough in organic chemistry: Asymmetric syntheses of useful, unique chiral compounds

Breakthrough in organic chemistry: Asymmetric syntheses of useful, unique chiral compounds
2021-02-16
Atropisomers are a class of stereoisomers (chemical compounds that differ in spatial arrangement of atoms) arising from restricted rotation around a single bond and have various applications in chemistry. To date, most research on atropisomers has focused on "biaryl atropisomers" (due to the rotational restriction around a carbon-carbon bond), but it is also possible for atropisomers to arise from rotational restrictions around a nitrogen-carbon (N-C) bond. These N-C axially chiral compounds are found in various natural products and bioactive compounds and thus have promising applications in medicine ...

LAST 30 PRESS RELEASES:

Scientists track evolution of pumice rafts after 2021 underwater eruption in Japan

The future of geothermal for reliable clean energy

Study shows end-of-life cancer care lacking for Medicare patients

Scented wax melts may not be as safe for indoor air as initially thought, study finds

Underwater mics and machine learning aid right whale conservation

Solving the case of the missing platinum

Glass fertilizer beads could be a sustained nutrient delivery system

Biobased lignin gels offer sustainable alternative for hair conditioning

Perovskite solar cells: Thermal stresses are the key to long-term stability

University of Houston professors named senior members of the National Academy of Inventors

Unraveling the mystery of the missing blue whale calves

UTA partnership boosts biomanufacturing in North Texas

Kennesaw State researcher earns American Heart Association award for innovative study on heart disease diagnostics

Self-imaging of structured light in new dimensions

Study highlights successes of Virginia’s oyster restoration efforts

Optimism can encourage healthy habits

Precision therapy with microbubbles

LLM-based web application scanner recognizes tasks and workflows

Pattern of compounds in blood may indicate severity of gestational hypertension and preeclampsia

How does innovation policy respond to the challenges of a changing world?

What happens when a diet targets ultra-processed foods?

University of Vaasa, Finland, conducts research on utilizing buildings as energy sources

Stealth virus: Zika virus builds tunnels to covertly infect cells of the placenta

The rising tide of sand mining: a growing threat to marine life

Contemporary patterns of end-of-life care among Medicare beneficiaries with advanced cancer

Digital screen time and nearsightedness

Postoperative weight loss after anti-obesity medications and revision risk after joint replacement

New ACS research finds low uptake of supportive care at the end-of-life for patients with advanced cancer

New frailty measurement tool could help identify vulnerable older adults in epic

Co-prescribed stimulants, opioids linked to higher opioid doses

[Press-News.org] New insight into antibody-induced protective immunity to COVID-19
Researchers at the Ragon Institute of MGH, MIT and Harvard and the Brigham and Women's Hospital collaborate with SpaceX to identify humoral immune features which may track with lasting protection against SARS-CoV-2.